EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cardioprotective antihyperglycemic drugs ameliorate endoplasmic reticulum stress

Arshag D Mooradian iD, Michael J Haas

American Journal of Physiology-Cell Physiology · 2024

DOI: 10.1152/ajpcell.00470.2023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, 2024. Verfasst von Arshag D Mooradian und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida Jacksonville College of Medicine, Jacksonville, Fl…. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: N/A.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cellular stress, notably oxidative, inflammatory, and endoplasmic reticulum (ER) stress, is implicated in the pathogenesis of cardiovascular disease. Modifiable risk factors for cardiovascular disease such as diabetes, hypercholesterolemia, saturated fat consumption, hypertension, and cigarette smoking cause ER stress whereas currently known cardioprotective drugs with diverse pharmacodynamics share a common pleiotropic effect of reducing ER stress. Selective targeting of oxidative stress with known antioxidative vitamins has been ineffective in reducing cardiovascular risk. This “antioxidant paradox” is partially attributed to the unexpected aggravation of ER stress by the antioxidative agents used. In contrast, some of the contemporary antihyperglycemic drugs inhibit both oxidative stress and ER stress in human coronary artery endothelial cells. Unlike sulfonylureas, meglitinides, α glucosidase inhibitors, and thiazolidinediones, metformin, glucagon-like peptide 1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors are the only antihyperglycemic drugs that reduce ER stress caused by pharmacological agents (tunicamycin) or hyperglycemic conditions. Clinical trials with selective ER stress modifiers are needed to test the suitability of ER stress as a therapeutic target for cardiovascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsCardiovascular DiseasesHumansEndothelial CellsEndoplasmic Reticulum StressAntioxidants

Stichwörter der Autor:innen

antihyperglycemic drugscardioprotectionendoplasmic reticulum stressglucagon-like peptide one receptor agonistssodium-glucose cotransporter two inhibitors

Substanzen

Hypoglycemic AgentsAntioxidants

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida Jacksonville College of Medicine, Jacksonville, Florida, United States.

ORCID-Profile: Arshag D Mooradian

Förderung

  • N/A

Zitieren

APA

Mooradian, A. D., & Haas, M. J. (2024). Cardioprotective antihyperglycemic drugs ameliorate endoplasmic reticulum stress. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00470.2023

Vancouver

Mooradian AD, Haas MJ. Cardioprotective antihyperglycemic drugs ameliorate endoplasmic reticulum stress. American Journal of Physiology-Cell Physiology. 2024. doi:10.1152/ajpcell.00470.2023

BibTeX
@article{Mooradian2024,
  author = {Mooradian, Arshag D and Haas, Michael J},
  title = {Cardioprotective antihyperglycemic drugs ameliorate endoplasmic reticulum stress},
  journal = {American Journal of Physiology-Cell Physiology},
  year = {2024},
  doi = {10.1152/ajpcell.00470.2023}
}
Kostenlos starten →